Cargando…
Predictive value of late gadolinium enhancement cardiovascular magnetic resonance in patients with persistent atrial fibrillation: dual-centre validation of a standardized method
AIMS: With recurrence rates up to 50% after pulmonary vein isolation (PVI) in persistent atrial fibrillation (AF), predictive tools to improve patient selection are needed. Patient selection based on left atrial late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) has been propo...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838794/ https://www.ncbi.nlm.nih.gov/pubmed/36654964 http://dx.doi.org/10.1093/ehjopen/oeac085 |
_version_ | 1784869354838425600 |
---|---|
author | Althoff, Till F Eichenlaub, Martin Padilla-Cueto, David Lehrmann, Heiko Garre, Paz Schoechlin, Simon Ferro, Elisenda Invers, Eric Ruile, Philipp Hein, Manuel Schlett, Christopher Figueras i Ventura, Rosa M Prat-Gonzalez, Susanna Mueller-Edenborn, Bjoern Bohnen, Marius Porta-Sanchez, Andreu Tolosana, Jose Maria Guasch, Eduard Roca-Luque, Ivo Arbelo, Elena Neumann, Franz-Josef Westermann, Dirk Sitges, Marta Brugada, Josep Arentz, Thomas Mont, Lluís Jadidi, Amir |
author_facet | Althoff, Till F Eichenlaub, Martin Padilla-Cueto, David Lehrmann, Heiko Garre, Paz Schoechlin, Simon Ferro, Elisenda Invers, Eric Ruile, Philipp Hein, Manuel Schlett, Christopher Figueras i Ventura, Rosa M Prat-Gonzalez, Susanna Mueller-Edenborn, Bjoern Bohnen, Marius Porta-Sanchez, Andreu Tolosana, Jose Maria Guasch, Eduard Roca-Luque, Ivo Arbelo, Elena Neumann, Franz-Josef Westermann, Dirk Sitges, Marta Brugada, Josep Arentz, Thomas Mont, Lluís Jadidi, Amir |
author_sort | Althoff, Till F |
collection | PubMed |
description | AIMS: With recurrence rates up to 50% after pulmonary vein isolation (PVI) in persistent atrial fibrillation (AF), predictive tools to improve patient selection are needed. Patient selection based on left atrial late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) has been proposed previously (UTAH-classification). However, this approach has not been widely established, in part owed to the lack of standardization of the LGE quantification method. We have recently established a standardized LGE-CMR method enabling reproducible LGE-quantification. Here, the ability of this method to predict outcome after PVI was evaluated. METHODS AND RESULTS: This dual-centre study (n = 219) consists of a prospective derivation cohort (n = 37, all persistent AF) and an external validation cohort (n = 182; 66 persistent, 116 paroxysmal AF). All patients received an LGE-CMR prior to first-time PVI-only ablation. LGE was quantified based on the signal-intensity-ratio relative to the blood pool, applying a uniform LGE-defining threshold of >1.2. In patients with persistent AF in the derivation cohort, left atrial LGE-extent above a cut-off value of 12% was found to best predict relevant low-voltage substrate (≥2 cm two with <0.5 mV during sinus rhythm) and arrhythmia-free survival 12 months post-PVI. When applied to the external validation cohort, this cut-off value was also predictive of arrhythmia-free survival for both, the total cohort and the subgroup with persistent AF (LGE < 12%: 80% and 76%; LGE > 12%: 55% and 44%; P = 0.007 and P = 0.029, respectively). CONCLUSION: This dual-centre study established and validated a standardized, reproducible LGE-CMR method discriminating PVI responders from non-responders, which may improve choice of therapeutic approach or ablation strategy for patients with persistent AF. |
format | Online Article Text |
id | pubmed-9838794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-98387942023-01-17 Predictive value of late gadolinium enhancement cardiovascular magnetic resonance in patients with persistent atrial fibrillation: dual-centre validation of a standardized method Althoff, Till F Eichenlaub, Martin Padilla-Cueto, David Lehrmann, Heiko Garre, Paz Schoechlin, Simon Ferro, Elisenda Invers, Eric Ruile, Philipp Hein, Manuel Schlett, Christopher Figueras i Ventura, Rosa M Prat-Gonzalez, Susanna Mueller-Edenborn, Bjoern Bohnen, Marius Porta-Sanchez, Andreu Tolosana, Jose Maria Guasch, Eduard Roca-Luque, Ivo Arbelo, Elena Neumann, Franz-Josef Westermann, Dirk Sitges, Marta Brugada, Josep Arentz, Thomas Mont, Lluís Jadidi, Amir Eur Heart J Open Original Article AIMS: With recurrence rates up to 50% after pulmonary vein isolation (PVI) in persistent atrial fibrillation (AF), predictive tools to improve patient selection are needed. Patient selection based on left atrial late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) has been proposed previously (UTAH-classification). However, this approach has not been widely established, in part owed to the lack of standardization of the LGE quantification method. We have recently established a standardized LGE-CMR method enabling reproducible LGE-quantification. Here, the ability of this method to predict outcome after PVI was evaluated. METHODS AND RESULTS: This dual-centre study (n = 219) consists of a prospective derivation cohort (n = 37, all persistent AF) and an external validation cohort (n = 182; 66 persistent, 116 paroxysmal AF). All patients received an LGE-CMR prior to first-time PVI-only ablation. LGE was quantified based on the signal-intensity-ratio relative to the blood pool, applying a uniform LGE-defining threshold of >1.2. In patients with persistent AF in the derivation cohort, left atrial LGE-extent above a cut-off value of 12% was found to best predict relevant low-voltage substrate (≥2 cm two with <0.5 mV during sinus rhythm) and arrhythmia-free survival 12 months post-PVI. When applied to the external validation cohort, this cut-off value was also predictive of arrhythmia-free survival for both, the total cohort and the subgroup with persistent AF (LGE < 12%: 80% and 76%; LGE > 12%: 55% and 44%; P = 0.007 and P = 0.029, respectively). CONCLUSION: This dual-centre study established and validated a standardized, reproducible LGE-CMR method discriminating PVI responders from non-responders, which may improve choice of therapeutic approach or ablation strategy for patients with persistent AF. Oxford University Press 2022-12-29 /pmc/articles/PMC9838794/ /pubmed/36654964 http://dx.doi.org/10.1093/ehjopen/oeac085 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Article Althoff, Till F Eichenlaub, Martin Padilla-Cueto, David Lehrmann, Heiko Garre, Paz Schoechlin, Simon Ferro, Elisenda Invers, Eric Ruile, Philipp Hein, Manuel Schlett, Christopher Figueras i Ventura, Rosa M Prat-Gonzalez, Susanna Mueller-Edenborn, Bjoern Bohnen, Marius Porta-Sanchez, Andreu Tolosana, Jose Maria Guasch, Eduard Roca-Luque, Ivo Arbelo, Elena Neumann, Franz-Josef Westermann, Dirk Sitges, Marta Brugada, Josep Arentz, Thomas Mont, Lluís Jadidi, Amir Predictive value of late gadolinium enhancement cardiovascular magnetic resonance in patients with persistent atrial fibrillation: dual-centre validation of a standardized method |
title | Predictive value of late gadolinium enhancement cardiovascular magnetic resonance in patients with persistent atrial fibrillation: dual-centre validation of a standardized method |
title_full | Predictive value of late gadolinium enhancement cardiovascular magnetic resonance in patients with persistent atrial fibrillation: dual-centre validation of a standardized method |
title_fullStr | Predictive value of late gadolinium enhancement cardiovascular magnetic resonance in patients with persistent atrial fibrillation: dual-centre validation of a standardized method |
title_full_unstemmed | Predictive value of late gadolinium enhancement cardiovascular magnetic resonance in patients with persistent atrial fibrillation: dual-centre validation of a standardized method |
title_short | Predictive value of late gadolinium enhancement cardiovascular magnetic resonance in patients with persistent atrial fibrillation: dual-centre validation of a standardized method |
title_sort | predictive value of late gadolinium enhancement cardiovascular magnetic resonance in patients with persistent atrial fibrillation: dual-centre validation of a standardized method |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838794/ https://www.ncbi.nlm.nih.gov/pubmed/36654964 http://dx.doi.org/10.1093/ehjopen/oeac085 |
work_keys_str_mv | AT althofftillf predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT eichenlaubmartin predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT padillacuetodavid predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT lehrmannheiko predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT garrepaz predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT schoechlinsimon predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT ferroelisenda predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT inverseric predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT ruilephilipp predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT heinmanuel predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT schlettchristopher predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT figuerasiventurarosam predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT pratgonzalezsusanna predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT muelleredenbornbjoern predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT bohnenmarius predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT portasanchezandreu predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT tolosanajosemaria predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT guascheduard predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT rocaluqueivo predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT arbeloelena predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT neumannfranzjosef predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT westermanndirk predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT sitgesmarta predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT brugadajosep predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT arentzthomas predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT montlluis predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod AT jadidiamir predictivevalueoflategadoliniumenhancementcardiovascularmagneticresonanceinpatientswithpersistentatrialfibrillationdualcentrevalidationofastandardizedmethod |